
Genetron Holdings Limited GTH
Annual report 2022
added 12-21-2024
Genetron Holdings Limited Book Value 2011-2026 | GTH
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Genetron Holdings Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 548 M | 1.21 B | 1.69 B | -1.78 B | -1.06 B | -622 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.69 B | -1.78 B | -2.27 M |
Quarterly Book Value Genetron Holdings Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 1.21 B | - | - | - | 1.69 B | - | - | - | -1.78 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.69 B | -1.78 B | 375 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 98.33 | 0.9 % | $ 8.11 B | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | ||
|
Brainsway Ltd.
BWAY
|
75.7 M | $ 13.71 | -0.22 % | $ 99.4 M | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 155.46 | 1.83 % | $ 7.71 B | ||
|
Bioventus
BVS
|
228 M | $ 8.62 | 0.23 % | $ 574 M | ||
|
DexCom
DXCM
|
2.75 B | $ 64.24 | -1.56 % | $ 25.1 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 25.56 | 0.95 % | $ 710 M | ||
|
CareDx, Inc
CDNA
|
303 M | $ 17.01 | 3.4 % | $ 906 M | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | $ 103.57 | 0.29 % | $ 19.5 B | ||
|
Guardant Health
GH
|
-99.3 M | $ 85.49 | 1.75 % | $ 10.7 B | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 14.77 | 0.61 % | $ 447 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
20.9 M | $ 17.88 | -6.63 % | $ 2.32 B | ||
|
Anixa Biosciences
ANIX
|
14 M | $ 2.83 | -1.05 % | $ 91.8 K | ||
|
Danaher Corporation
DHR
|
83.5 B | $ 187.32 | 0.57 % | $ 134 B | ||
|
IQVIA Holdings
IQV
|
6.63 B | $ 164.72 | 1.1 % | $ 28.3 B | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
6.3 B | $ 118.94 | 2.92 % | $ 18.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 199.7 | -0.46 % | $ 22.2 B | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
5.39 B | $ 111.51 | -0.06 % | $ 33.9 B | ||
|
BioNano Genomics
BNGO
|
35.4 M | $ 1.11 | -0.89 % | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 9.0 | -0.99 % | $ 255 M | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 9.09 | -2.78 % | $ 1.97 B | ||
|
National Research Corporation
NRC
|
14 M | $ 16.52 | 0.12 % | $ 370 M | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.33 | 4.72 % | $ 399 M | ||
|
Co-Diagnostics
CODX
|
86 M | - | - | $ 79.8 M | ||
|
Medpace Holdings
MEDP
|
459 M | $ 450.41 | 1.48 % | $ 13 B | ||
|
Celcuity
CELC
|
116 M | $ 114.22 | 3.11 % | $ 4.51 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 173.74 | 0.49 % | $ 24.2 B | ||
|
Personalis
PSNL
|
203 M | $ 6.72 | 1.97 % | $ 398 M | ||
|
NeoGenomics
NEO
|
837 M | $ 7.88 | -1.25 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
706 M | $ 187.85 | -1.29 % | $ 18.5 B | ||
|
Sotera Health Company
SHC
|
606 M | $ 13.42 | 0.71 % | $ 3.81 B | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | ||
|
OPKO Health
OPK
|
1.37 B | $ 1.19 | 2.59 % | $ 826 M |